JPMorgan analyst Robbie Marcus lowered the firm’s price target on Integra LifeSciences (IART) to $11 from $13 and keeps an Underweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences price target lowered to $12 from $13 at Wells Fargo
- Integra LifeSciences files automatic mixed securities shelf
- Integra LifeSciences reports Q4 adjusted EPS 83c, consensus 80c
- Integra LifeSciences sees 2026 adjusted EPS $2.30-$2.40, consensus $2.35
- Integra LifeSciences sees Q1 adjusted EPS 37c-45c, consensus 48c